Clinical Trial Update: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands [Phase 1]

View source ↗

Summary

Phase 1 safety study of CYAD-01, CAR T cells targeting NKG2D-ligands, completed; evaluated in acute myeloid leukemia, myelodysplastic syndromes, and multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Multiple Myeloma
• Myelodysplastic Syndrome

Drugs mentioned

• CYAD-01 (NKG2D-ligand-targeting chimeric antigen receptor T cells)

Snippet

Sponsor: Celyad Oncology SA | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED